169
Participants
Start Date
June 30, 2012
Primary Completion Date
March 31, 2015
Study Completion Date
September 30, 2015
DR cysteamine bitartrate capsule
"* 600 mg/day (four 75 mg capsules twice daily) for patients ≤ 65 kg at baseline~* 750 mg/day (five 75 mg capsules twice daily) for patients \>65 - 80 kg at baseline~* 900 mg/day (six 75 mg capsules twice daily) for patients \>80 kg at baseline"
DR cysteamine bitartrate placebo
"* 600 mg/day (four 75 mg capsules twice daily) for patients ≤ 65 kg at baseline~* 750 mg/day (five 75 mg capsules twice daily) for patients \>65 - 80 kg at baseline~* 900 mg/day (six 75 mg capsules twice daily) for patients \>80 kg at baseline"
Columbia University, New York
Emory University, Atlanta
Indiana University, Indianapolis
St. Louis University, St Louis
Texas Children's Hospital, Houston
University of California, San Diego, San Diego
University of California, San Francisco, San Francisco
University of Washington, Seattle Children's Hospital, Seattle
Ann & Robert H. Lurie Children's Hospital of Chicago (NWU), Chicago
Cincinnati Children's Hospital Medical Center, Cincinnati
Collaborators (1)
National Center for Advancing Translational Sciences (NCATS)
NIH
National Cancer Institute (NCI)
NIH
Raptor Pharmaceuticals
UNKNOWN
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
NIH